Literature DB >> 19942232

Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients.

Derya Tilki1, Robert S Svatek, Pierre I Karakiewicz, Hendrik Isbarn, Oliver Reich, Wassim Kassouf, Yves Fradet, Giacomo Novara, Hans-Martin Fritsche, Patrick J Bastian, Jonathan I Izawa, Christian G Stief, Vincenzo Ficarra, Seth P Lerner, Mark Schoenberg, Colin P Dinney, Eila Skinner, Yair Lotan, Arthur I Sagalowsky, Shahrokh F Shariat.   

Abstract

PURPOSE: We describe cancer specific outcomes in patients with pT4 bladder urothelial carcinoma at radical cystectomy in a large international cohort.
MATERIALS AND METHODS: We reviewed the records of 4,257 patients treated with radical cystectomy for bladder urothelial carcinoma at 12 centers. No patient received any preoperative systemic chemotherapy or radiotherapy.
RESULTS: Of the 4,257 patients 583 (14%) had pT4 bladder urothelial carcinoma, of whom 83.7% were male, 85.2% had substage pT4a disease, 24.9% had positive soft tissue surgical margins, 57.8% had lymphovascular invasion and 53.5% had lymph node metastasis. Median followup was 55.0 months. Overall estimated 5-year recurrence-free and cancer specific survival was 29% (95% CI 22-32) and 31% (95% CI 25-36), respectively. On multivariate analysis female gender (p = 0.005 and p = 0.001), positive soft tissue surgical margins (p = 0.014 and p <0.001), lymphovascular invasion (p = 0.016 and p = 0.005), pT4b substage (p = 0.041 and p = 0.002, respectively) and lymph node involvement (each p <0.001) were independently associated with disease recurrence and cancer specific mortality.
CONCLUSIONS: Patients with pT4 bladder urothelial carcinoma have highly variable outcomes. Features associated with metastatic tumor dissemination (ie lymph node invasion and lymphovascular invasion) and local disease burden (ie soft tissue surgical margins and pT4 substage) are associated with poor outcomes in patients with pT4 bladder urothelial carcinoma. Further research is needed to understand why female patients with pT4 bladder urothelial carcinoma have a worse outcome than their male counterparts.

Entities:  

Mesh:

Year:  2010        PMID: 19942232     DOI: 10.1016/j.juro.2009.08.145

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Clinicopathologic characteristics and overall survival in patients with bladder cancer involving the gastrointestinal tract.

Authors:  Amber M D'Souza; Gary S Phillips; Kamal S Pohar; Debra L Zynger
Journal:  Virchows Arch       Date:  2013-10-04       Impact factor: 4.064

Review 2.  Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer.

Authors:  Marianne Schmid; Shahrokh F Shariat; Armin Soave; Oliver Engel; Margit Fisch; Michael Rink
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

3.  Gender-dependent cancer-specific survival following radical cystectomy.

Authors:  Matthias May; Christian Stief; Sabine Brookman-May; Wolfgang Otto; Christian Gilfrich; Jan Roigas; Mario Zacharias; Wolf F Wieland; Hans-Martin Fritsche; Ferdinand Hofstädter; Maximilian Burger
Journal:  World J Urol       Date:  2011-10-09       Impact factor: 4.226

Review 4.  Impact of gender on bladder cancer incidence, staging, and prognosis.

Authors:  Harun Fajkovic; Joshua A Halpern; Eugene K Cha; Atessa Bahadori; Thomas F Chromecki; Pierre I Karakiewicz; Eckart Breinl; Axel S Merseburger; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-06-09       Impact factor: 4.226

5.  Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.

Authors:  Eric C Kauffman; Brian D Robinson; Martin J Downes; Leagh G Powell; Ming Ming Lee; Douglas S Scherr; Lorraine J Gudas; Nigel P Mongan
Journal:  Mol Carcinog       Date:  2011-03-11       Impact factor: 4.784

6.  Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy.

Authors:  Bastian Keck; Oliver J Ott; Lothar Häberle; Frank Kunath; Christian Weiss; Claus Rödel; Rolf Sauer; Rainer Fietkau; Bernd Wullich; Frens S Krause
Journal:  World J Urol       Date:  2012-10-23       Impact factor: 4.226

7.  Prognostic impact of infiltration of the vagina and/or uterus in women undergoing anterior pelvic exenteration for urothelial carcinoma of the bladder: results of a contemporary multicentre series.

Authors:  Matthias May; Atiqullah Aziz; Sabine Brookman-May; Florian Roghmann; Joachim Noldus; Michael Rink; Felix Chun; Margit Fisch; Vladimir Novotny; Manfred Wirth; Roman Mayr; Armin Pycha; Antonin Brisuda; Björn Volkmer; Regina Stredele; Christopher Dechet; Stefan Vallo; Axel Haferkamp; Marco Schnabel; Stefan Denzinger; Jan Roigas; Christian G Stief; Christian Gilfrich; Patrick J Bastian; Jörg B Engel; Maximilian Burger; Hans-Martin Fritsche
Journal:  World J Urol       Date:  2014-05-10       Impact factor: 4.226

8.  Gender-specific survival following radical cystectomy for pT4 bladder cancer.

Authors:  Dharam Kaushik; Igor Frank; Manuel S Eisenberg; John C Cheville; Robert Tarrell; Prabin Thapa; R Houston Thompson; Stephen A Boorjian
Journal:  World J Urol       Date:  2013-12-21       Impact factor: 4.226

9.  Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.

Authors:  Luis A Kluth; Harun Fajkovic; Evanguelos Xylinas; Joseph J Crivelli; Niccolo Passoni; Morgan Rouprêt; Andreas Becker; Evi Comploj; Armin Pycha; Sten Holmang; Amit Gupta; Yair Lotan; Pierre I Karakiewicz; Paolo Gontero; Felix K-H Chun; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  World J Urol       Date:  2012-11-30       Impact factor: 4.226

10.  Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC).

Authors:  Ali Al-Daghmin; Eric C Kauffman; Yi Shi; Ketan Badani; M Derya Balbay; Erdem Canda; Prokar Dasgupta; Reza Ghavamian; Robert Grubb; Ashok Hemal; Jihad Kaouk; Adam S Kibel; Thomas Maatman; Mani Menon; Alex Mottrie; Kenneth Nepple; John G Pattaras; James O Peabody; Vassilis Poulakis; Raj Pruthi; Juan Palou Redorta; Koon-Ho Rha; Lee Richstone; Francis Schanne; Douglas S Scherr; Stefan Siemer; Michael Stöckle; Eric M Wallen; Alon Weizer; Peter Wiklund; Timothy Wilson; Gregory Wilding; Michael Woods; Khurshid A Guru
Journal:  BJU Int       Date:  2014-05-22       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.